Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Masonic Cancer Center, University of Minnesota
Age
12–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
HCT recipients over 12 years of age within the first 7 days of initial treatment of high-risk aGVHD, defined as:
Newly diagnosed Minnesota high-risk aGVHD -OR-
Newly diagnosed Minnesota standard risk aGVHD with plasma amphiregulin ≥ 33 pg/ml tested at the UMN Cytokine Reference Lab. For amphiregulin lab ordering information, see Fairview Lab Guide: http://labguide.fairview.org/showtest.asp?testid=6766\&format=long -OR-
Newly diagnosed Minnesota standard risk aGVHD Ann Arbor 3 biomarkers tested by Viracor. For ordering information, see: https://www.viracor-eurofins.com/test-menu/403572p-agvhd-symptomatic- onset-algorithm/
* Renal: Serum creatinine ≤2.5x upper limit of normal (ULN)
* Cardiac: Left ventricular ejection fraction (LVEF) ≥ 35%
* Voluntary written consent (adult or parent/guardian with minor assent for 12 through 17-year-olds).
You may not be if
Progressive malignancy
Uncontrolled bacterial, fungal, parasitic, or viral infection at initiation of protocol treatment
Unwilling or unable to stop supplemental sex hormone therapy (estrogen, progesterone, and/or testosterone preparations)
Unwilling or unable to stop GnRH antagonists, aromatase inhibitors, or anti-androgens
History of a hormone responsive malignancy
Current thromboembolic disease requiring full-dose anticoagulation - patients receiving pharmacologic prophylaxis for thromboembolic disease will be eligible
Active or recent (within prior 3 months) thrombus, irrespective of anticoagulation status
Pregnancy
Women or men of childbearing potential unwilling to take adequate precautions to avoid unintended pregnancy from the start of protocol treatment through 30 days after the last treatment
Clareo Health | Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids
